CDX2 and acute myeloid leukemia: Over 90% of AML cases overexpress CDX2 (Chase et al., 1999; Scholl et al., 2007; Rawat et al., 2008), and ectopic expression of Cdx2 confers oncogenic properties to murine HSCs (Rawat et al., 2004; Scholl et al., 2007).